Current status and prospects for development of an HSV vaccine

Vaccine. 2014 Mar 20;32(14):1553-60. doi: 10.1016/j.vaccine.2013.08.066. Epub 2013 Sep 6.


Herpes simplex virus type 2 (HSV-2) infects 530million people, is the leading cause of genital ulcer disease, and increases the risk of HIV-1 acquisition. Although several candidate vaccines have been promising in animal models, prophylactic and therapeutic vaccines have not been effective in clinical trials thus far. Null results from the most recent prophylactic glycoprotein D2 subunit vaccine trial suggest that we must reevaluate our approach to HSV-2 vaccine development. We discuss HSV-2 pathogenesis, immunity, and vaccine efforts to date, as well as the current pipeline of candidate vaccines and design of trials to evaluate new vaccine constructs.

Keywords: Genital herpes; Herpes simplex virus; Vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Epitopes, T-Lymphocyte / immunology
  • Herpes Genitalis / immunology
  • Herpes Genitalis / prevention & control*
  • Herpes Simplex Virus Vaccines / immunology*
  • Herpes Simplex Virus Vaccines / therapeutic use
  • Herpesvirus 2, Human*
  • Humans
  • Immunity, Mucosal
  • Vaccination / trends
  • Vaccines, Subunit / immunology
  • Viral Envelope Proteins / immunology


  • Epitopes, T-Lymphocyte
  • Herpes Simplex Virus Vaccines
  • Vaccines, Subunit
  • Viral Envelope Proteins
  • glycoprotein D-herpes simplex virus type 2